Enables Labs to Quickly Ramp up Testing Capacity and Generate Results Faster
WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 17, 2020– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a series of explorer™ workstations for SARS-CoV-2 testing capable of preparing and running up to 10,000 COVID-19 tests per day. These modular and scalable workstations enable laboratories to ramp up SARS-CoV-2 testing capacity quickly to generate results.
Currently many laboratories are unable to deliver COVID-19 testing results in a timely manner. Slow results and delayed responses can increase the risk of further spread of the disease.
PerkinElmer’s scalable and modular explorer automated workstations streamline testing workflows, speeding up SARS-CoV-2 RT-PCR and ELISA testing. The workstations help laboratories improve their efficiency, while eliminating errors. In addition, they reduce labor requirements by automating and standardizing disparate workflow steps. They also provide varying degrees of automation based on workload and staffing resources.
To better respond to the COVID-19 pandemic, laboratories need the ability to obtain all workflow components – from reagents to equipment, to consumables at the scale they need, when they need them. Today, PerkinElmer is able to deliver these workflow components globally.
“The global economy is reeling from this pandemic, and laboratories need to be able to rapidly scale their testing capacity up and down,” said Masoud Toloue, Ph.D., Vice President and General Manager, Diagnostics, PerkinElmer. “PerkinElmer is developing innovative solutions giving laboratories the flexibility they need to meet the ever-changing COVID-19 testing demand. The best-in-class explorer workstations enable laboratories to efficiently work through the COVID-19 pandemic.”
PerkinElmer has more than 20 years of experience in optimizing complete workflows (including reagents, equipment, and consumables) based on testing, throughput, and staffing requirements. The Company’s comprehensive SARS-CoV-2 offerings span high throughput RNA extraction, RT-PCR assays, automation, ELISA, and other laboratory solutions. Its ELISA offerings are available through EUROIMMUN, a PerkinElmer company.
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our failure to adequately protect our intellectual property; (7) the loss of any of our licenses or licensed rights; (8) our ability to compete effectively; (9) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (10) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (11) disruptions in the supply of raw materials and supplies; (12) the manufacture and sale of products exposing us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with healthcare industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005119/en/
Media Relations:
Chet Murray
(781) 663-5719
chet.murray@perkinelmer.com
Investor Relations:
Bryan Kipp
(781) 663-5583
bryan.kipp@perkinelmer.com
Source: PerkinElmer, Inc.